Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEBNASDAQ:FBIONASDAQ:FLKSNASDAQ:ONCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$1.18-2.5%$1.22$0.80▼$3.20$48.48M-1.1318,182 shs3,368 shsFBIOFortress Biotech$1.75-1.1%$1.60$1.33▼$2.89$51.68M1.82406,671 shs102,648 shsFLKSFlex Pharma$0.71+1.7%$6.86$0.26▼$1.49$12.83M1.652.03 million shs58,518 shsONCYOncolytics Biotech$0.55-3.6%$0.60$0.47▼$1.53$47.53M1.07527,356 shs258,285 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+2.54%+24.74%-6.92%-23.90%-58.28%FBIOFortress Biotech+1.14%+11.32%+13.46%-0.56%+5.99%FLKSFlex Pharma0.00%+5.92%-19.03%-71.39%+39.88%ONCYOncolytics Biotech-3.56%+0.74%+3.78%-22.02%-48.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANEBAnebulo Pharmaceuticals2.017 of 5 stars3.53.00.00.01.81.70.0FBIOFortress Biotech2.3732 of 5 stars3.50.00.00.03.33.30.6FLKSFlex PharmaN/AN/AN/AN/AN/AN/AN/AN/AONCYOncolytics Biotech1.5502 of 5 stars3.53.00.00.01.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 3.00Buy$8.00577.97% UpsideFBIOFortress Biotech 3.00Buy$21.001,100.00% UpsideFLKSFlex Pharma 0.00N/AN/AN/AONCYOncolytics Biotech 3.00Buy$4.33687.88% UpsideCurrent Analyst Ratings BreakdownLatest FLKS, FBIO, ONCY, and ANEB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/11/2025FBIOFortress BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $16.003/10/2025ONCYOncolytics BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.003/10/2025ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/10/2025ONCYOncolytics BiotechRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$6.00 ➝ $5.002/3/2025ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/AFBIOFortress Biotech$57.68M0.90N/AN/A$0.10 per share17.50FLKSFlex Pharma$840K15.27N/AN/A$0.51 per share1.39ONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.20M-$0.28N/A∞N/AN/A-119.54%-108.08%5/13/2025 (Estimated)FBIOFortress Biotech-$60.64M-$2.78N/AN/AN/A-84.53%N/A-34.93%5/13/2025 (Estimated)FLKSFlex Pharma-$21.92MN/A0.00∞N/A-1,208.42%-98.04%-83.37%N/AONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-141.15%-84.73%5/8/2025 (Estimated)Latest FLKS, FBIO, ONCY, and ANEB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q3 2025ANEBAnebulo Pharmaceuticals-$0.05N/AN/AN/AN/AN/A5/21/2025Q1 2025FBIOFortress Biotech-$0.44N/AN/AN/A$11.62 millionN/A5/8/2025Q1 2025ONCYOncolytics Biotech-$0.09N/AN/AN/AN/AN/A3/31/2025Q4 2024FBIOFortress Biotech-$0.79-$0.26+$0.53-$0.26$16.30 million$15.12 million2/14/2025Q2 2025ANEBAnebulo PharmaceuticalsN/A-$0.09N/A-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/AFLKSFlex PharmaN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A17.5117.51FBIOFortress BiotechN/A1.231.06FLKSFlex PharmaN/A6.866.74ONCYOncolytics BiotechN/A2.992.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%FBIOFortress Biotech96.51%FLKSFlex Pharma14.42%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%FBIOFortress Biotech33.40%FLKSFlex Pharma7.62%ONCYOncolytics Biotech0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.09 million5.79 millionNot OptionableFBIOFortress Biotech17029.53 million18.39 millionOptionableFLKSFlex Pharma418.07 millionN/ANot OptionableONCYOncolytics Biotech3086.42 million85.42 millionNot OptionableFLKS, FBIO, ONCY, and ANEB HeadlinesRecent News About These CompaniesOncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of ActionApril 24, 2025 | prnewswire.comAs Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer TreatmentsApril 14, 2025 | baystreet.caOncolytics Biotech Secures $20 Million Funding for Pelareorep DevelopmentApril 10, 2025 | tipranks.comOncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni CapitalApril 10, 2025 | prnewswire.comOncolytics Biotech® and Pelareorep Discussed DuringApril 10, 2025 | kxan.comOncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic CancersApril 10, 2025 | prnewswire.comOncolytics price target lowered to $3 from $5 at MaximMarch 10, 2025 | markets.businessinsider.comOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comOncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call TranscriptMarch 7, 2025 | seekingalpha.comOncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024March 7, 2025 | prnewswire.comOncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMarch 5, 2025 | zacks.comWorld Cancer Day Sparks Big Questions About Pollution, Genetics, and InnovationFebruary 27, 2025 | baystreet.caUSA News Group: Oncology Breakthroughs: How Cancer Research Is Advancing in 2025February 27, 2025 | finanznachrichten.deOncolytics Biotech to Discuss 2024 Financial Results and Operational HighlightsFebruary 25, 2025 | tipranks.comOncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational HighlightsFebruary 25, 2025 | prnewswire.comOncolytics Biotech advances pancreatic, anal cancer trialsFebruary 20, 2025 | markets.businessinsider.comUSA News Group: Investors Eye Biotech Sector as Cancer Therapy Market SurgesFebruary 19, 2025 | finanznachrichten.deOncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025February 19, 2025 | prnewswire.comOncolytics provides progress update for pelareorep in pancreatic and anal cancerFebruary 18, 2025 | markets.businessinsider.comOptimism in War on Cancer on the Rise, as Biotech Companies Roll Out More WinsFebruary 18, 2025 | baystreet.caNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFLKS, FBIO, ONCY, and ANEB Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$1.18 -0.03 (-2.48%) Closing price 04:00 PM EasternExtended Trading$1.18 0.00 (-0.42%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Fortress Biotech NASDAQ:FBIO$1.75 -0.02 (-1.13%) Closing price 04:00 PM EasternExtended Trading$1.75 0.00 (0.00%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Flex Pharma NASDAQ:FLKSFlex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.Oncolytics Biotech NASDAQ:ONCY$0.55 -0.02 (-3.64%) Closing price 04:00 PM EasternExtended Trading$0.57 +0.02 (+3.64%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
